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Abstract The HER2 amplicon on chromosome 17q is
variable in size and occasionally includes Topoisomerase 2A
(TOP2A) at 17q21-22. It has been suggested that TOP2 co-
amplification, not HER2 amplification on chromosome
17q11.2-12, is a useful predictive marker of response to
anthracycline-based chemotherapy in breast cancer patients.
Given the significant toxicities of anthracyclines, the
detection methods of TOP2A gene amplifications have to be
standardized. We determined TOP2A gene alterations using
two different fluorescence in situ hybridization (FISH) DNA
probes. HER2 amplifications were identified with the Path-
VysionTM probe. TOP2A status of 42 HER2 amplified breast
cancers was tested by FISH with PathVysionTM covering
160 kb and DAKO pharm DXTM covering 228 kb of the
TOP2A amplicon. TOP2A protein expression was tested by
immunohistochemistry. Multiplex-ligation dependent probe
amplification (MLPA) was performed retrospectively in
cases showing discrepancies. TOP2A was amplified in 15 of
42 cases (35%) with DAKO pharm DXTM and in 11 of 42
cases (26%) with PathVysionTM. In all four discrepant cases,
MLPA showed no TOP2A amplification, but instead
amplification of an upstream region including HER2.
TOP2A was deleted in the same seven of 42 carcinomas
(17%) with both probes. TOP2A protein expression was
detected in all 42 tumours (100%) with high intratumoral
heterogeneity. TOP2A amplification rate depends on the
length of the hybridized probes for the TOP2A locus.
Because TOP2A, not HER2, is a target of anthracyclines,
non-overlapping DNA probes should be used to evaluate any
associations between such alterations and response to
anthracycline-based chemotherapy.
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Introduction
Currently, anthracyclines represent the main adjuvant
treatment of early stage breast cancer. Not all patients
benefit from such treatment and these agents have signifi-
cant toxicities. Evaluation of the TOP2A gene in HER2
positive breast cancer has been recently addressed as a
predictor of the response to anthracycline-based chemo-
therapy [9, 20, 21]. HER2 positive patients with simulta-
neously amplified TOP2A gene were associated with longer
survival and increased response to anthracycline-based
chemotherapy than HER2 positive patients without TOP2A
amplification [9, 14, 18, 21, 23]. HER2 expression alone
does not alter anthracycline sensitivity. Furthermore, HER2
and TOP2A co-amplification predicts improved overall and
disease free survival more reliably in breast cancer patients
[1, 14]. Conversely, lack of TOP2A gene amplification (i.e.
a normal gene status or a deletion of the TOP2A) has been
associated with anthracycline resistance [1, 21, 23].
HER2 is located on chromosome 17q11.2-12. In vivo
and in vitro studies have shown that HER2 overexpression
alone does not alter anthracycline sensitivity [11]. TOP2A
at 17q21-22 is in close proximity to HER2, resulting in a
proportion of HER2 amplified breast cancer cases also
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containing co-amplification of TOP2A [12, 13, 16].
Because TOP2A is a target of anthracyclines, it is possible
that this gene, not HER2, is responsible for anthracycline
responsiveness [21].
Larger studies have shown that 33–60% of HER2 posi-
tive cancers contain concurrent TOP2A amplifications,
while 20–42% are TOP2A deleted. According to some
studies, TOP2A alterations are extremely rare in the
absence of HER2 amplification, while others report a
10–20% TOP2A amplification or deletion rate in HER2
negative breast cancer [6, 10, 20, 21].
This wide variability may have different causes and is
likely related to the fluorescence in situ hybridization
(FISH) technology. Fluorescence or chromogenic labelled
in situ hybridization technology (FISH, CISH) or immu-
nohistochemistry (IHC) have been the choice of methods in
many previous studies [1, 4–6, 14, 18, 20–23]. Numerical
analysis of TOP2A gene alterations has been conducted in
many studies in an analogous way as it is usually done in
HER2 testing and a cut-off [2 TOP2A/CEP17 ratio was
used to determine an amplified TOP2A status [5, 6, 14, 18,
21, 23]. Deletion of the TOP2A gene conversely has been
set to different TOP2A/CEP17 ratios ranging from 0.5 to 1
[5–7, 14, 18, 20].
In the current study, we addressed the question whether
the rate of TOP2A amplification and deletion depends on
the length of the FISH detection probes using different
FISH probes (PathVysionTM and DAKO pharm DXTM).
Materials and methods
Patients
Forty-two consecutive HER2 amplified breast cancer
patients were selected from the diagnostic service of the
Institute of Surgical Pathology, University Hospital Zurich.
HER2 status was primarily determined with fluorescence in
situ hybridisation (FISH) during routine diagnostics. All
tumours had a HER2/CEP17 ratio of more than 2.2. Mean
age of patients was 57 years (range 29 to 95 years). Par-
affin blocks with tumour tissue were available in all cases.
All analyses were carried out on whole tissue sections.
Thirty-four of 42 cases (81%) were invasive ductal
carcinomas, 8 cases (19%) corresponded to special types of
breast cancer (5 micropapillary, 2 invasive pleomorphic
lobular carcinomas and 1 case of clear cell mammary
carcinoma).
Twenty of 42 patients had hormone receptor positive
carcinomas (48%), 22 of 42 patients had hormone receptor
negative carcinomas (52%). Tumours were graded accord-
ing to the modified Bloom and Richardson grading system
for invasive breast cancer [24]. Thirty-six carcinomas (86%)
were poorly differentiated, and 6 cases (14%) were moder-
ately differentiated.
TOP2A immunohistochemistry
Protein expression was determined immunohistochemi-
cally on 2-lm thick paraffin embedded sections by using a
mouse anti TOP2A monoclonal primary antibody (DAKO,
DakoCytomation, Denmark A/S, Glostrup, clone: M7186,
dilution: 1:400). The entire procedure was carried out on
the Ventana Benchmark automated staining system by
applying Ventana reagents. Pretreatment was performed by
cooking with CC1-Buffer (Ventana) for 36 min at 95C.
TOP2A antibody was detected by the iVIEW DAB
detection kit and the signal was enhanced using the
amplification kit.
As to stain intensity and specificity of TOP2A immu-
nohistochemistry, we analysed normal breast tissue on
large sections in a similar fashion as seen with MIB-1 or
ER immunohistochemistry. Vessels and interstitial spaces
were not stained, only nuclei in the ductulo-lobular units
was stained. TOP2A immunohistochemistry was scored as
follows: clear nuclear staining regardless of stain intensity
was considered as positive. The extent of positive cells was
estimated semi-quantitatively over the tumour area on
intermediate power view (109 magnification) and was
scored in a percentage.
TOP2A fluorescence in situ hybridisation
TOP2A gene status on 17q21-22 was determined by using
two dual colour DNA probe kits and a three colour DNA
probe kit (Fig. 1).
Fig. 1 Graphical illustration of the hybridized DNA length for
TOP2A and HER2
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Kit 1: TOP2A/CEP17 (PathVysionTM, Code Nr: 32-
190095, Vysis, Abbott AG, Diagnostic Division Baar,
Switzerland).
This dual colour probe hybridizes the TOP2A gene on
17q21-q22 labelled with spectrum orange. The DNA
clones cover a total of 160 kb of the TOP2A amplicon on
17q21-q22. The centromer (CEP17) is hybridized with
spectrum green on 17p11.1-q11.1.
Kit 2: TOP2A/HER2/CEP17 (PathVysionTM, Code Nr:
32-19095, Vysis, Abbott AG, Diagnostic Division Baar,
Switzerland).
This three colour probe contains the HER2 Gene
(17q11.2-q12, labelled with spectrum green), the CEP17
region (17p11.1-q11.1, labelled with spectrum aqua) and
the TOP2A gene (17q21-q22, labelled with spectrum
orange). The DNA clones cover a total of 160 kb of the
TOP2A amplicon on 17q21-q22 and a total of 190 kb of the
HER2 amplicon on 17q11.2-q12.
Kit 3: TOP2A/CEP17 (DAKO pharm DXTM, Code Nr.:
K5333, DakoCytomation, Denmark A/S, Glostrup).
This dual probe contains a mixture of TOP2A gene and
CEP17. The TOP2A gene is labelled with Texas Red,
which covers a total of 228 kb of the TOP2A amplicon on
17q21-q22. The CEP17 is labelled with spectrum green
and covers the region of 17p11.1-q11.1.
For all fluorescence in situ hybridization analyses, par-
affin embedded sections of two micrometer thickness were
used. All procedures for the FISH analyses were carried out
by following the recommended protocol of the manufac-
turers. Probe mixes were hybridized at 37C between 14
and 20 h, washed in Rapid-Wash-Solution I at 73C for
5 min, Rapid-Wash-Solution II and H2O for 7 min, air
dried and counterstained with DAPI. The analysis was
done by using an Olympus computer guided fluorescence
microscope (BX61). For each tumour case, a new haema-
toxylin and eosin (H&E) stain was available in order to
identify the invasive tumour component.
Scoring of all FISH kits was performed according to
the recommendations in the literature [1, 6, 21]. The
absolute copy number of both CEP17 and TOP2A were
counted and manually transferred into an excel data sheet.
If gene copies were present in clusters, they were recor-
ded as clusters. Following recommendation for clusters in
the ASCO/CAP guidelines for HER2 testing, larger clus-
ters were documented as equivalent of approximately
12–14 gene copies per cluster [26, 27]. Each FISH reac-
tion was additionally documented on at least one digital
photograph.
Deletion of TOP2A gene was defined as the presence of
one gene copy in more than 90% of the examined area.
Amplification of the TOP2A gene was defined as at least 6
gene copies in a minimum of 100 invasive tumour cells. As
aneuploidy of higher grade was not a relevant feature in
this cancer cohort, it was not necessary to measure TOP2A/
CEP17 ratio. TOP2A gene status was considered as normal
if the gene copy number was at least 2 and did not exceed 5
gene copies.
Immunohistochemistry and FISH reactions were carried
out by one technician (SB), the reactions were analysed
and scored by one pathologist (ZV).
Multiplex-ligation dependent probe amplification
(MLPA)
This assay was conducted retrospectively on those cases
which revealed discrepant amplification status with the
FISH probes. The test was performed as previously
described using the P004-C1 chromosome 17 kit (MRC-
Holland, Amsterdam, The Netherlands) containing 3
TOP2A probes [15, 16]. All tests were performed on an
ABI 9700 PCR machine (Applied Biosystems, Foster City,
CA, USA) and fragment analyses were run on an ABI 3730
DNA Analyser (Applied Biosystems). Copy number ratios
were analysed using Genemapper (Applied Biosystems)
and Coffalyser software (MRC-Holland). For genes with
more than one probe present in the kit, the mean of all the
probe peaks of this gene in duplicate was calculated. A
mean value below 0.7 was defined as loss, a value between
0.7–1.3 was defined as normal, 1.3–2.0 as gain and values
[2.0 were defined as (high level) amplification, as estab-
lished previously [3].
Results
TOP2A immunohistochemistry
There was heterogeneous TOP2A positivity in all 42 car-
cinomas. In 4 of 42 cases (9.5%) immunopositivity was
found in 10% of the tumour cells. In 38 of 42 cases
(90.5%), immunopositive nuclei were detected in more
than 10% of the tumour cells (on average 50–80%). There
was no correlation between TOP2A immunopositivity and
TOP2A copy number by FISH.
TOP2A and CEP17 fluorescence in situ hybridisation
(Fig. 2)
Kit 1 and 2 (PathVysionTM):
The FISH analysis with the dual and the three colour probe
kits resulted in completely identical results.
CEP17 was diploid in 31 of 42 cases (74%) and aneu-
ploid (3–4 gene copies) in 11 cases (26%). There was no
monosomy or aneuploidy of higher grade ([ 4 copies) of
CEP17 detected.
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TOP2A was diploid in 9 cases (21%), deletion was
found in 7 cases (17%). Low-aneuploidy (3–5 gene copies)
was present in 15 cases (36%). Amplification of the TOP2A
was present in 11 cases (26%). Among the amplified cases,
TOP2A copy number reached 6–8 in 4 tumours. TOP2a
was present in smaller clusters in 7 other amplified cases.
Kit 3 (DAKO pharm DXTM):
CEP17 was diploid in 33 of 42 cases (79%) and aneuploid
(3–4 gene copies) in 8 cases (19%). Monosomy was
detected in one case (2%). Aneuploidy of higher grade ([4
copies) of CEP17 was not detected.
TOP2A was diploid in 8 of 42 cases (19%), deletion was
found in 7 cases (17%). Low-aneuploidy (3–5 gene copies)
was present in 12 cases (28%). Amplification of the TOP2A
gene was present in 15 cases (36%). Among the amplified
cases, TOP2A copy number was 6–8 in 6 cases, larger
clusters or in more than 12 gene copies were detected in 9
cases.
Multiplex-ligation dependent probe amplification (MLPA)
The four cases with discrepant amplification status with the
FISH probes, showed amplification of the HER2 gene,
GRB7 and IKZF3 (one of the cases also RARA) but no
amplification of the TOP2A gene with the MLPA meth-
odology. The TOP2A copy number ratios of the four dis-
crepant cases were 0.86, 1.07, 1.21 and 0.99.
FISH and IHC results are summarised in Table 1.
Discussion
In our study, a discrepancy in the HER2/TOP2A co-
amplification status was observed in 4 of 42 patients using
different TOP2A probes. TOP2A was amplified in 26% by
PathVysionTM and in 35% using DAKO pharmTM probe.
There was no difference in the detection rate of TOP2A
gene deletion. Both probes identified 7 identical cases with
TOP2A gene deletion. Deletion or amplification of the
TOP2A gene did not show any correlation to TOP2A
protein expression. All 42 tumours showed at least 10%
nuclear TOP2A positivity.
The results of our study suggest that the difference in
detection rate of TOP2A amplification is due to the dif-
ferent length of the DNA probes hybridising to the TOP2A
region (17q21-q22). The DAKO pharmTM probe covers a
total of 228 kb of the TOP2A region, while the Pathvy-
sionTM probe envelops a shorter DNA segment of 160 kb.
The external MPLA control could not detect amplification
of the TOP2A gene in any on the four discrepant cases;
however, the HER2 gene was amplified with this meth-
odology. These results strongly imply that the larger
TOP2A DNA probe most likely overlaps with the HER2
gene region and thus results in ‘overdetection’.
Differential detection rate depending on the length of
the mapping probe has also been identified by Jacobson
et al., by using three different probes of Genome Systems
covering three regions telomeric from the HER2 gene [7].
Jacobson et al. [7] reported that the TOP2A amplification
rate varies from 23–46% depending on the length of the
Fig. 2 Different patterns of fluorescent in situ hybridisation (FISH)
for TOP2A, HER2 and CEP17 in HER2 positive breast cancer
samples. All reactions originate from the series with PathVysionTM
kit. Coloration: TOP2A: orange, HER2: green, CEP17: aqua.
a Normal TOP2A status (2 gene copies). CEP17 is present in 2
copies, the HER2 gene in up to 10 gene copies. b Deletion of TOP2A
gene: one copy of TOP2a, three copies of CEP17 (aneusomic), small
clusters and up to 8 copies of the HER2 gene. c Amplification of
TOP2A gene: TOP2a, three copies of CEP17 (aneusomic), small
clusters and up to 8 copies of the HER2 gene
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hybridizing probe, which is very similar to our results.
Interestingly, a differential TOP2A gene deletion was
detected as well, ranging from 8 to 23% [7]. In our study,
TOP2A gene deletion rate was found in 7 identical cases
(17%), independently of the FISH probe. The length of the
FISH probe apparently does not influence the detection of
gene deletion.
Amplification rate of the TOP2A gene in HER2 ampli-
fied breast cancer has been reportedly as high as 35% on
average varying from 7 to 50% [4, 6–10, 14, 20, 21]. The
variable incidence of TOP2A aberrations is most likely due
to heterogenous study populations, divergent cut-offs/
scoring systems as well as to the different specificity of the
in situ hybridisation probes used for detection [2, 6, 20,
21]. Literature data are based on at least two different
in situ hybridisation kits including fluorescent (FISH)
and chromogenic (CISH) technology of three different
companies (DAKO pharmTM, PathvysionTM and Zymed)
[1, 4–6, 14, 18, 20–23, 25].
As to scoring of TOP2A gene numeration, in most
studies an analogous system to HER2 scoring has been
applied using a cut-off [2 TOP2A/CEP17 to determine an
amplified TOP2A status [5, 6, 14, 18, 21, 23]. However, in
some earlier studies, TOP2A amplification was defined as a
TOP2A/CEP17 ratio [1.5 [4, 7, 20]. When using the
absolute copy number for TOP2A amplification, most
studies set the cut-off of at least 6 TOP2A gene copies [1,
23]. The same is true for the definition of TOP2A gene
allelic deletion in the literature. Cut-offs for deletion
include different TOPAa/CEP17ratios ranging from\0.50,
\0.70, \0.75, \0.8 to \1.0 [5–7, 14, 18, 20].
In most studies, TOP2A gene amplification has been
detected in a setting of co-amplification with the HER2
gene, but rarely in HER2 non-amplified patients [6, 20, 21].
The two genes are located on two distinct chromosomal
regions and deletion of the TOP2A gene can commonly
occur in the presence of HER2 amplification [7, 8]. HER2
gene amplification is often accompanied by co-amplifica-
tion of several adjacent genes comprising 17q12-q21,
e.g. TOP2A or RARA [12, 13, 16]. It is important to note,
that both commercially available TOP2A FISH probes
hybridize a DNA region, which is positioned approxi-
mately 679 kb in distance from the HER2 gene [17, 19].
Intratumoral heterogeneity of TOP2A gene signals can
give an additional explanation on conflicting literature data
regarding the frequency of TOP2A gene alterations [7, 10].
The number of cells showing TOP2A gene alterations can
be largely influenced by the material used for the study:
cell lines, imprint preparations, tissue microarrays or whole
tissue sections can result in different percentages of TOP2A
altered cells due to the heterogeneous distribution of the
altered cells [7, 10]. As described by Jarvinen et al. [7, 10],
TOP2A amplified and deleted cells can be found within the
same tumour. Such heterogeneity was seen in up to 14% of
breast cancer samples [7, 10]. Interestingly, the critical
evaluation of our breast cancer samples revealed intratu-
moral heterogeneity of TOP2A alterations in most breast
carcinomas. We did not see mixed patterns of deleted or
amplified cells, but rather a mixture of amplified and nor-
mal cells or deleted and normal cells within the same
tumour. This is in contrast to the HER2 gene amplification
in our cohort, which was in general a homogenous finding
over the whole tissue sections.
Therapeutic benefit of adjuvant anthracycline containing
regiments at HER2 and TOP2A positive breast cancer
patients has been controversial. Depending on the study
cohort and diagnostic criteria for TOP2A status determi-
nation, predictive and prognostic value of HER2 and/or
TOP2A amplification for treatment response could be
confirmed or questioned in several previous mostly retro-
spective studies [1, 2, 14, 18, 21–23, 25]. Tubbs et al. [25]
reported earlier in a prospective tissue microarray based
study that HER2 gene status and not TOP2A gene altera-
tions are prognostic in anthracycline treated patients. Data
from another prospective recent trial by Press et al. [21]
demonstrate that TOP2A co-amplification but not HER2
amplification is the clinically predictive marker for
response to anthracycline-based chemotherapy.
This discrepancy cannot be explained by technical
issues, because DNA probe kits from PathVysionTM and
the same cut-offs for signal interpretation were used in both
studies [21, 25]. It is more likely that the interpretation of a
Table 1 Summary of TOP2A status via FISH testing and Immunohistochemistry (IHC) in 42 HER2 amplified breast cancers
TOP2A amplified
PathVysionTM
TOP2A amplified DAKO
pharmTM
TOP2A deletion
PathVysionTM
TOP2A deletion DAKO
pharmTM
Top2A
IHC
ER positive
n = 20
5 (25%) 7 (36%) 5 (25%) 5 (25%) 20 (100%)
ER negative
n = 22
6 (22%) 8 (36%) 2 (9%) 2 (9%) 22 (100%)
Total n = 42 11 (26%) 15 (35%) 7 (17%) 7 (17%) 42 (100%)
ER estrogene receptors
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heterogeneous distribution of TOP2A alterations has
caused divergent results in both tissue microarray based
studies [21, 25].
A recent meta-analysis from five randomised adjuvant
trials suggests that not only patients with HER2 gene
amplified tumours, but also those with non-amplified HER2
and normal TOP2A status can benefit from anthracycline-
based adjuvant therapy [15]. In this meta-analysis, Leo
et al. [15] propose the need for increased standardisation in
TOP2A testing by FISH methodology due to suboptimal
reproducibility.
The biological relevance of TOP2A protein overex-
pression is controversial. Arriola et al. [1, 14] reported that
TOP2A protein overexpression correlates to high prolifer-
ation fraction, hormone receptor positivity and either to
HER2 or to basal phenotype. Moelans et al. [12, 13, 16]
found an association between TOP2A overexpression and
TOP2A gene amplification but not with gene deletion.
According to our data, TOP2A protein was expressed in all
breast cancer cases independently of any other factors.
In summary, our data clearly underscore the relevance
of appropriate standardisation of the FISH technology and
probes for TOP2A testing with predictive purposes. Addi-
tional testing, for example MLPA technology to double-
check amplification status, is a possibility to be addressed
in future studies.
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